Overview
Lobbying Costs
1,000,000€ - 1,249,999€
Financial year: Jan 2023 - Dec 2023
Lobbyists (Full time equivalent)
3.25 Fte (12)
Lobbyists with EP accreditation
3
High-level Commission meetings
4
Lobbying Costs over the years
-
Info
Amgen Inc
EU Transparency Register
42243575237-50 First registered on 07 Feb 2011
Goals / Remit
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Amgen was incorporated in California in 1980 and became a Delaware corporation in 1987. Amgen has a presence in approximately 100 countries worldwide. It operates in one business segment : human therapeutics.
Main EU files targeted
Engage governments and policy makers worldwide on issues important to Amgen to: Ensure patients have access to medicines they need. Provide coverage and reimbursement that reward innovation
Introduce sound, science-based regulation. Enable biotechnology research and development (R&D)Address
Head Office
One Amgen Center Drive
Thousand Oaks, California 91320-1799
UNITED STATESEU Office
5-7 Telecomlaan
Diegem
BELGIUMWebsite
-
People
Total lobbyists declared
12
Employment time Lobbyists 75% 1 50% 2 25% 4 10% 5 Lobbyists (Full time equivalent)
3.25
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
3 accreditations were / are live (in bold) for the selected state of 21 Nov 2024
Name Start date End Date Olivia McDermid 12 Nov 2024 11 Nov 2025 Alicia ROJO SANTOS 10 Oct 2024 09 Oct 2025 Nicholas COSENZA 20 Sep 2024 19 Sep 2025 Nicholas COSENZA 23 Sep 2023 21 Sep 2024 Viktoria TZOUMA 09 Mar 2024 04 Oct 2024 Vincent MARTICHOU 13 Jul 2023 12 Jul 2024 Viktoria TZOUMA 02 Feb 2023 02 Feb 2024 Marie Helene FANDEL 26 Feb 2019 01 Feb 2020 Douglas GREGORY 24 Jan 2019 24 Jan 2020 Mr Jamie Nathan WILKINSON 20 Nov 2018 20 Nov 2019 Vincent MARTICHOU 27 Mar 2018 30 Mar 2019 Marie Helene FANDEL 16 Feb 2018 16 Feb 2019 Douglas GREGORY 30 Jan 2018 24 Jan 2019 Douglas GREGORY 25 Feb 2017 30 Jan 2018 Marie Helene FANDEL 25 Feb 2017 16 Feb 2018 Janusz LINKOWSKI 05 Sep 2016 26 Aug 2017 Douglas GREGORY 14 Jan 2016 13 Jan 2017 Marie Helene FANDEL 16 Sep 2015 14 Sep 2016 Janusz LINKOWSKI 05 Sep 2015 03 Sep 2016 Ms JOANA MARIA GANDARA LEITAO PAIVA 23 Jan 2015 23 Oct 2015 Douglas GREGORY 23 Jan 2015 14 Jan 2016 Ms JOANA MARIA GANDARA LEITAO PAIVA 15 Mar 2014 23 Jan 2015 Douglas GREGORY 01 Mar 2014 23 Jan 2015 Douglas GREGORY 07 Mar 2013 28 Feb 2014 Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
Amgen is a member of the following organizations in Brussels:
AmCham EU - American Chamber of Commerce to the EU
EFPIA – European Federation of Pharmaceutical Industries and Associations
Eucope - European Confederation of Pharmaceutical Entrepreneurs
EPC - European Policy Centre
Friends of Europe
European Business SummitMember organisations
N.A.
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2023 - Dec 2023
Lobbying costs for closed financial year
1,000,000€ - 1,249,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount hanover 100,000€ - 199,999€ brunswick 100,000€ - 199,999€ acumen 50,000€ - 99,999€ Intermediaries for current year
Name acumen brunswick hanover Closed year Costs
1,000,000€ - 1,249,999€
Other financial info
Increase in annual amount declared due to acquisition of Horizon Therapeutics, which already had activities covered by the scope of the Register.
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
None
Other activities
None declared
Meetings
Meetings
4 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.
-
Date 10 Oct 2024 Location Brussels Subject EB Summit Cabinet Cabinet of President Ursula von der Leyen Attending - Peter van Kemseke (Cabinet member)
Other Lobbyists -
Date 08 Jul 2022 Location call Subject pharmaceutical supply chains Cabinet Cabinet of Commissioner Thierry Breton Portfolio Internal Market Attending - Maurits-Jan Prinz (Cabinet member)
-
Date 12 Jun 2020 Location Videoconference Subject Videoconference CEO of Amgen and CEO of Teneo (Topic: Preparation of Global Pledging Summit on 27 June) Cabinet Cabinet of President Ursula von der Leyen Portfolio President Attending - Ursula von der Leyen (President)
Other Lobbyists -
Date 17 May 2018 Location Brussels Subject Digital Health Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Digital Economy and Society Attending - Manuel Mateo-Goyet (Cabinet member)